Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Medtronic
Fuji
Baxter
Mallinckrodt
Novartis
US Army
McKinsey
Cerilliant
US Department of Justice

Generated: August 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
Inventor(s): Bang-Andersen; Benny (Copenhagen S, DK), Mork; Arne (Malov, DK), Stensbol; Tine Bryan (Vaerlose, DK), Faldt; Andre (Ishoj, DE)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Filing Date:Sep 09, 2014
Application Number:14/481,000
Claims:1. A method of treating cognitive impairment involving decline in speed of processing, executive function, attention, or verbal learning and memory in a patient diagnosed with depression, the method comprising administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to the patient, wherein Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine and the method alleviates a symptom or complication of the cognitive impairment or delays the progression of the cognitive impairment.

2. The method of claim 1, wherein Compound I or a pharmaceutically acceptable salt thereof is a hydrobromide salt of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

3. The method of claim 1, wherein the depression is major depressive disorder.

4. The method of claim 1, wherein the method comprises administering a hydrobromide, hydrochloride, mesylate, fumarate, maleate, meso-tartrate, L-(+)-tartrate, D-(-)-tartrate, sulphate, phosphate or nitrate salt of Compound I to the patient.

5. The method of claim 3, wherein the method comprises administering a hydrobromide, hydrochloride, mesylate, fumarate, maleate, meso-tartrate, L-(+)-tartrate, D-(-)-tartrate, sulphate, phosphate or nitrate salt of Compound I to the patient.

6. The method of claim 3, wherein the method comprises administering a hydrobromide salt of Compound I to the patient.

7. The method of claim 1, wherein the depression is generalized depression.

8. The method of claim 1, wherein the depression is postnatal depression.

9. The method of claim 1, wherein the depression is a depression associated with bipolar disorder.

10. The method of claim 1, wherein the depression is a treatment resistant depression.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Queensland Health
McKesson
Cantor Fitzgerald
Covington
Farmers Insurance
US Army
UBS
Mallinckrodt
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot